| 罗敬轩.半乳糖凝集素-3与特发性肺纤维化相关性研究进展[J].安徽医药,待发表. |
| 半乳糖凝集素-3与特发性肺纤维化相关性研究进展 |
|
| 投稿时间：2025-03-30 录用日期：2025-04-24 |
| DOI： |
| 中文关键词: 半乳糖凝集素-3 特发性肺纤维化 间充质转化 信号通路 治疗策略 |
| 英文关键词: |
| 基金项目:甘肃省科技计划项目(20JR10RA697) |
|
| 摘要点击次数: 44 |
| 全文下载次数: 0 |
| 中文摘要: |
| 特发性肺纤维化（IPF）是一种以持续性肺泡结构损伤和异常纤维瘢痕形成为特征的慢性肺疾病，其病理过程涉及肺间质受累，最终导致换气功能障碍和呼吸衰竭。半乳糖凝集素-3（Gal-3）是一种多功能的碳水化合物结合蛋白，已被证实参与肝、肾、心脏等器官的纤维化进程。近期研究表明Gal-3的异常表达与IPF的发生和进展密切相关，有望成为IPF的生物标志物和抗纤维化治疗的新靶点。本文综述Gal-3在IPF中的作用机制及治疗前景，为IPF的研究和治疗提供新思路。 |
| 英文摘要: |
| Idiopathic Pulmonary fibrosis (IPF) is a chronic lung disease characterized by persistent alveolar structural damage and abnormal fibrotic scarring, involving interstitial lung tissue and ultimately leading to impaired gas exchange and respiratory failure. Galectin-3 (Gal-3) is a multifunctional carbohydrate-binding protein that has been shown to participate in the fibrotic processes of various organs, including the liver, kidneys, and heart. Recent studies indicate that the abnormal expression of Gal-3 is closely associated with the onset and progression of IPF, suggesting its potential as both a biomarker and a therapeutic target for antifibrotic treatment. This review summarizes the role and underlying mechanisms of Gal-3 in IPF, as well as its therapeutic prospects, aiming to provide new insights for IPF research and treatment. |
|
查看/发表评论 下载PDF阅读器 |
| 关闭 |
